[Effect of bromocriptine on secretion of the enzyme dopamine-B-hydroxylase (DBH) in patients with Parkinson's disease].
The activity of DBH enzyme was measured in plasma of 7 non treated patients suffering from Parkinson's disease; a 10 mg dose of Bromocryptine was administered per os to these patients. Attained results were compared to the enzyme activity in a group of control of 7 healthy individuals. It was pointed out that in patients suffering from Parkinson's disease the decrease  of DBH level in plasma after the administration of Bromocryptine was of 32.6% +/- SE 4.4% while in the group of control the decrease was only of 15% +/- SE 4.9%. This decrease in the plasmatic level of the enzyme after the administration of Bromocryptine should be due to the marked antagonistic activity of Bromocryptine on pre-synaptic dopaminergic receptors. This should mean that peripheric pre-synaptic dopaminergic receptors are involved in the physiopathology of Parkinson's disease.
D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology
D001971:Bromocriptine; D004299:Dopamine beta-Hydroxylase
L'effetto della Bromocriptina sulla secrezione dell'enzima dopamina-B-idrossilasi (DBH) nei malati de Parkinson.